Genetics said lowering Lp(a) should help. An 8,323-person trial just tested that.

On 4 September 2026, Novartis announced that its Phase 3 trial of pelacarsen — a drug designed specifically to lower lipoprotein(a), or Lp(a) — had failed to meet its primary goal. The drug did exactly what it was built to do, chemically: it lowered Lp(a) levels in the 8,323 patients enrolled, all of whom already had elevated Lp(a) and established cardiovascular disease. What it did not do was reduce the actual outcome anyone cared about — a composite of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent hospitalization for coronary revascularization.

Novartis's own chief medical officer put it plainly: lower Lp(a) levels were observed, but that did not translate into reduced cardiovascular risk in the overall study population.

Why this was surprising — and it genuinely was

This site's own Lipoprotein(a) Levels page already covers a study that pointed the opposite direction, and pointed there over fifteen years ago. Clarke et al. 2009, the PROCARDIS consortium, compared 3,145 people with coronary disease against 3,352 controls, replicated in 4,846 more cases and 4,594 more controls. The study found two variants in the LPA gene — rs10455872 and rs3798220 — each independently associated with both higher Lp(a) level and higher coronary disease risk. People carrying both variants had more than double the odds of coronary disease compared to people carrying neither.

The detail that made this more than a correlation: when the researchers statistically adjusted for Lp(a) level itself, the genetic variants' association with coronary disease risk disappeared entirely. That is the textbook signature geneticists look for when arguing a measured biomarker sits on the actual causal pathway to disease, rather than just riding alongside it for some unrelated reason. This kind of evidence — genetic variants that raise a biomarker and raise disease risk together, with the disease risk explained away once you account for the biomarker — is exactly why Lp(a)-lowering drugs like pelacarsen seemed like a promising idea in the first place.

Two real findings, not fully reconciled

Both things are true at once: people who are genetically predisposed to higher Lp(a) really do carry higher cardiovascular risk in a way that traces back through Lp(a) itself, and a drug that pharmacologically lowered Lp(a) in a large, well-conducted trial did not reduce cardiovascular events. This site is not going to pretend to resolve that contradiction — nobody has, yet, with certainty. Possibilities being discussed elsewhere include the trial population already being on intensive standard-of-care treatment that narrowed the room for additional benefit, the specific mechanism of an antisense-oligonucleotide drug differing from a lifetime of genetically lower Lp(a) in ways that matter, or the relationship being real but smaller than the genetic estimate suggested. This page states the contrast because saying so honestly is more useful than picking whichever finding is more convenient.